We show that a pretreatment approach of VEN followed by CTLs minimizes toxicity of VEN on CTLs while still leading to enhanced AML cell killing, including of the CD34+/CD38− compartment, compared to either therapy alone. The gene discussed is CD38; the disease is acute myeloid leukemia.